The market expansion of antibacterial quinolones

I. Hermecz, M. Ecsery-Puskas

Research output: Contribution to journalArticle

Abstract

The third generation of quinolones developed in the 1980's was a breakthrough in the practice of antibacterial treatment. Several medicines belonging to this group have been launched on the Hungarian market in the 1990's. The overwhelming success of these medicines is the result of their therapeutic effectiveness offering an alternative to other antibiotics. The present study describes their increasing sales and applications both worldwide and in Hungary. The most important derivatives, such as ciprofloxacin with a worldwide sales of 1 billion USD, ofloxacin norfloxacin and pefloxacin have become available in Hungary by now. In addition to sales in Hungary data of preparations sold in the USA, UK, Germany, France, Italy and Austria are also demonstrated. The place of quinolones among the systematic antibiotics is demonstrated through their sales data. The last part of this paper analyses the average daily costs of quinolone treatments and the average costs of full treatments of the above mentioned six countries, and for Germany and Hungary, compares these data to those of other antibiotics sold for similar therapeutic purpose.

Original languageEnglish
Pages (from-to)513-523
Number of pages11
JournalGyogyszereszet
Volume37
Issue number8
Publication statusPublished - 1993

Fingerprint

Hungary
Quinolones
Anti-Bacterial Agents
Germany
Pefloxacin
Norfloxacin
Ofloxacin
Austria
Ciprofloxacin
Health Care Costs
Italy
France
Costs and Cost Analysis
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hermecz, I., & Ecsery-Puskas, M. (1993). The market expansion of antibacterial quinolones. Gyogyszereszet, 37(8), 513-523.

The market expansion of antibacterial quinolones. / Hermecz, I.; Ecsery-Puskas, M.

In: Gyogyszereszet, Vol. 37, No. 8, 1993, p. 513-523.

Research output: Contribution to journalArticle

Hermecz, I & Ecsery-Puskas, M 1993, 'The market expansion of antibacterial quinolones', Gyogyszereszet, vol. 37, no. 8, pp. 513-523.
Hermecz, I. ; Ecsery-Puskas, M. / The market expansion of antibacterial quinolones. In: Gyogyszereszet. 1993 ; Vol. 37, No. 8. pp. 513-523.
@article{d41087be8e7a47268efabd9a0b0948fc,
title = "The market expansion of antibacterial quinolones",
abstract = "The third generation of quinolones developed in the 1980's was a breakthrough in the practice of antibacterial treatment. Several medicines belonging to this group have been launched on the Hungarian market in the 1990's. The overwhelming success of these medicines is the result of their therapeutic effectiveness offering an alternative to other antibiotics. The present study describes their increasing sales and applications both worldwide and in Hungary. The most important derivatives, such as ciprofloxacin with a worldwide sales of 1 billion USD, ofloxacin norfloxacin and pefloxacin have become available in Hungary by now. In addition to sales in Hungary data of preparations sold in the USA, UK, Germany, France, Italy and Austria are also demonstrated. The place of quinolones among the systematic antibiotics is demonstrated through their sales data. The last part of this paper analyses the average daily costs of quinolone treatments and the average costs of full treatments of the above mentioned six countries, and for Germany and Hungary, compares these data to those of other antibiotics sold for similar therapeutic purpose.",
author = "I. Hermecz and M. Ecsery-Puskas",
year = "1993",
language = "English",
volume = "37",
pages = "513--523",
journal = "Gyogyszereszet",
issn = "0017-6036",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "8",

}

TY - JOUR

T1 - The market expansion of antibacterial quinolones

AU - Hermecz, I.

AU - Ecsery-Puskas, M.

PY - 1993

Y1 - 1993

N2 - The third generation of quinolones developed in the 1980's was a breakthrough in the practice of antibacterial treatment. Several medicines belonging to this group have been launched on the Hungarian market in the 1990's. The overwhelming success of these medicines is the result of their therapeutic effectiveness offering an alternative to other antibiotics. The present study describes their increasing sales and applications both worldwide and in Hungary. The most important derivatives, such as ciprofloxacin with a worldwide sales of 1 billion USD, ofloxacin norfloxacin and pefloxacin have become available in Hungary by now. In addition to sales in Hungary data of preparations sold in the USA, UK, Germany, France, Italy and Austria are also demonstrated. The place of quinolones among the systematic antibiotics is demonstrated through their sales data. The last part of this paper analyses the average daily costs of quinolone treatments and the average costs of full treatments of the above mentioned six countries, and for Germany and Hungary, compares these data to those of other antibiotics sold for similar therapeutic purpose.

AB - The third generation of quinolones developed in the 1980's was a breakthrough in the practice of antibacterial treatment. Several medicines belonging to this group have been launched on the Hungarian market in the 1990's. The overwhelming success of these medicines is the result of their therapeutic effectiveness offering an alternative to other antibiotics. The present study describes their increasing sales and applications both worldwide and in Hungary. The most important derivatives, such as ciprofloxacin with a worldwide sales of 1 billion USD, ofloxacin norfloxacin and pefloxacin have become available in Hungary by now. In addition to sales in Hungary data of preparations sold in the USA, UK, Germany, France, Italy and Austria are also demonstrated. The place of quinolones among the systematic antibiotics is demonstrated through their sales data. The last part of this paper analyses the average daily costs of quinolone treatments and the average costs of full treatments of the above mentioned six countries, and for Germany and Hungary, compares these data to those of other antibiotics sold for similar therapeutic purpose.

UR - http://www.scopus.com/inward/record.url?scp=0027364759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027364759&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 513

EP - 523

JO - Gyogyszereszet

JF - Gyogyszereszet

SN - 0017-6036

IS - 8

ER -